Biological properties of lactoferrin: An overview

Australian Journal of Dairy Technology

Volumn 62, Issue 1, 2007, Pages 31-42

  Pan, Y ^a,c   Rowney, M ^a   Guo, P ^b   Hobman, P ^a  

^a MG Nutritionals   (Australia)

^b CSIRO   (Australia)

^c Murray Goulburn Co operative Co Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); MAMMALIA; NEGIBACTERIA; POSIBACTERIA;

EID: 34249719615     PISSN: 00049433     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (217)

1. Adamik, B., Zimecki, M., Wlaszczyk, A., Berezowicz, P. and Kubler, A. (1998), Lactoferrin effects on the in vitro immune response in critically ill patients. Arch. Immun. Ther. Exp. 46, 169-176.
2. Aguila, A., Herrera, A.G., Morrison, D., Cosgrove, B., Perojo, A., Montesinos, I., Pèrez, J., Sierra, G., Gemmell, C.G. and Brock, J.H. (2001), Bacteriostatic activity of human lactoferrin against Staphylococcus aureus is a function of its iron-binding properties and is not influenced by antibiotic resistance. FEMS Immun. Med. Microbiol. 31, 145-152.
3. Ajello, M., Greco, R., Giansanti, F., Massucci, M.T., Antonini, G. and Valenti, P. (2002), Anti-invasive activity of bovine lactoferrin towards Group a Streptococci. Biochem. Cell Biol. 80, 119-124.
4. Al-Nabulsi, A.A. and Holley, R.A. (2006), Enhancing the antimicrobial effects of bovine lactoferrin against Escherichia coli O157:H7 by cation chelation, NaCl and temperature. J. Appl. Microbiol. 100, 244-255.
5. Amini, H.R., Ascencio, F., Ruiz-Bustos, E., Romero, M.J. and Wadströ, M.T. (1996), Cryptic domains of a 60 kDa heat shock protein of Helicobacter pylori bound to bovine lactoferrin. FEMS Immun. Med. Microbiol. 16, 247-255.
6. Andersson, Y., Lindquist, S., Lagerqvist, C. and Hernell, O. (2000), Lactoferrin is responsible for the fungistatic effect of human milk. Early Human Develop. 59, 95-105.
7. Appelmelk, B.J., An, Y.Q., Geerts, M., Thijs, B.G., de Boer, H.A., Mac Laren, D.M., de Graaf, J. and Nuijens, J.H. (1994), Lactoferrin is a lipid A-binding protein. Infect. Immun. 62, 2628-2632.
8. Arnold, R.R., Russel, J.E., Champion, W.J., Brewer, M. and Gauthier, J.J. (1982), Bactericidal activity of lactoferrin: differentiation from the stasis of iron deprivation. Infect. Immun. 35, 792-799.
9. Arnold, D., Di Biase, A.M., Marchetti, M., Pietrantoni, A., Valenti, P., Seganti, L. and Superti, F. (2002), Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res. 53, 153-158.
10. Artym, J., Zimecki, M. and Kruzel, M.L. (2004), Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin. Int. Immunopharmacol. 4, 1149-1157.
11. Artym, J. and Zimecki, M. (2005), The role of lactoferrin in the proper development of newborns. Postepy. Hig. Med. Dosw. (Online) 59, 421-432.
12. Artym, J., Zimecki, M., Kuryszko, J. and Kruzel, M.L. (2005), Lactoferrin accelerates reconstitution of the humoral and cellular immune response during chemotherapy-induced immunosuppression and bone marrow transplant in mice. Stem Cells Dev. 14, 548-555.
13. Babina, S.E., Kanyshkova, T.G., Buneva, V.N. and Nevinsky G.A. (2004), Lactoferrin is the major deoxyribonuclease of human milk. Biochem. (Mosc). 69, 1006-1015.
14. Babina, S.E. and Nevinsky, G.A. (2004), Lactoferrin interacts with nucleotides. Nucleic Acids 23, 1043-1046.
15. Babina, S.E., Semenov, D.V., Buneva, V.N. and Nevinskii, G.A. (2005), Human milk lactoferrin hydrolyzes nucleoside-5′-triphosphates. Mol. Biol. (Mosk) 39, 513-520.
16. Babina, S.E., Tuzikov, F.V., Tuzikova, N.A., Buneva, V.N. and Nevinskii, G.A. (2006), The effect of nucleotides on oligomeric state of human lactoferrin. Mol. Biol. (Mask.) 40, 137-149.
17. Baker, E.N., Baker, H.M. and Kidd, R.D. (2002), Lactoferrin and transferrin: functional variations on a common structural framework. Biochem. Cell Biol. 80, 27-34.
18. Baumrucker, C.R., Schanbacher, F., Shang, Y. and Green, M.H. (2006), Lactoferrin interaction with retinoid signaling: cell growth and apoptosis in mammary cells. Dornest. Anim. Endocrinol. 30, 289-303.
19. Baveye, S., Elass, E., Mazurier, J., Spik, G. and Legrand, D. (1999), Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin. Chem. Lab. Med. 37, 281-286.
20. Bellamy, W., Takase, H., Wakabayashi, K., Kawase, K. and Tomita, M. (1992a), Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacterial. 73, 472-479.
21. Bellamy, W., Takase, M., Yamauchi, K., Wakabayashi, H., Kawase, K. and Tomita, M. (1992b), Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta. 1121, 130-136.
22. Beljaars, L., van der Strate, B.W., Bakker, H.I., Reker-Smit, C., van Loenen-Weemaes, A. M.,Wiegmans, F.C., Harmsen, M.C., Molema, G. and Meijer, D.K. (2004), Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antiviral Res. 63, 197-208.
23. Benaissa, M., Peyrat, J.P., Hornez, L., Mariller, C., Mazurier, J. and Pierce, A. (2005), Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer. Int. J. Cancer 114, 299-306.
24. Berkhout, B., Derksen, G.C.H., Back, N.K.T., Klaver, B., Kruif, C.G. and Visser, S. (1997), Structural and functional analysis of negatively charged milk proteins with Anti-HIV activity. AIDS Res. Human Retroviruses 13, 1101-1107.
25. Berkhout, B., Van Wamel, J.L.B., Beljaars, L., Meijer, D.K.F., Visser, S. and Floris, R. (2002), Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res. 55, 341-355.
26. Bishop, J.G., Schanbacher, F.L., Ferguson, L.C. and Smith, K.L. (1976), In vitro growth inhibition of mastitis-causing coli form bacteria by bovine apo-lactoferrin and reversal of inhibition by citrate and high concentrations of apo-lactoferrin. Infect. Immun. 14, 911-915.
27. Boesman-Finkelstein, M. and Finkelstein, R.A. (1985), Antimicrobial effects of human milk: inhibitory activity on enteric pathogens. FEMS Microbiol. Lett. 27, 167-174.
28. Bolscher, J.G., van der Kraan, M.I., Nazmi, K., Kalay, H., Grun, C.H., Van't Hof, W., Veerman, E.C. and Nieuw Amerongen, A.V. (2006), A one-enzyme strategy to release an antimicrobial peptide from the LFampin-domain of bovine lactoferrin. Peptides 27, 1-9.
29. Branen, J.K. and Davidson, P.M. (2004), Enhancement of nisin, lysozyme, and monolaurin antimicrobial activities by ethylenediaminetetraacetic acid and lactoferrin. Int. J. Food Microbiol. 90, 63-74.
30. Brock, J.H. (1980), Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the new-born infant. Arch. Dis. Child. 55, 417-421.
31. Chand, R.K., Sahoo, P.K., Kumari, J., Pillai, B.R. and Mishra, B.K. (2006), Dietary administration of bovine lactoferrin influences the immune ability of the giant freshwater prawn Macrobrachium rosenbergii (de Man) and its resistance against Aeromonas hydrophila infection and nitrite stress. Fish Shellfish Immunol. 21, 119-129.
32. Chapple, D.S., Mason, D.J., Joannou, C.L., Odell, E.W., Gant, V. and Evans, R.W. (1998), Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111. Infect. Immun. 66, 2434-2440.
33. Chodaczek, G., Zimecki, M., Lukasiewicz, J. and Lugowski, C. (2006), A complex of lactoferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice. Meet. Microbiol. Immunol. (Berl.) 195, 207-216.
34. Coddeville, B., Strecker, G., Wieruszeski, J.M., Vliegenthart, J.F.G., van Halbeek, H., Peter-Katalinic, J., Egge, H. and Spik, G. (1992), Heterogeneity of bovine lactotransferrin glycans. Carb. Res. 236, 145-164.
35. Cohen, M.S., Mao, J., Rasmussen, G.T., Serody, J.S. and Britigan, B.E. (1992), Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J. Infect. Dis. 166, 1375-1378.
36. Cornish, J., Callon, K.E., Naot, D., Palmano, K.P., Banovic, T., Bava, U., Watson, M., Lin, J.M., Tong, P.C., Chen, Q., Chan, V.A., Reid, H.E., Fazzalari, N., Baker, H.M., Baker, E.N., Haggarty, N.W., Grey, A.B. and Reid, I.R. (2004), Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology 145, 4366-4374.
37. Crouch, S.P.M., Slater, K.J. and Fletcher, J. (1992), Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 80, 235-240.
38. 2+. Amer. J. Physiol. 257, G930-G934.
39. De Oliveira, I.R., De AraúJo, A.N., Bao, S.N. and Giugliano, L.G. (2001), Binding of lactoferrin and free secretory component to enterotoxigenic Escherichia coli. FEMS Microbiol. Lett. 203, 29-33.
40. Dial, E.J., Hall, L.R., Serna, H., Romero, J.J., Fox, J.G. and Lichtenberger, L.M. (1998), Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Digest. Dis. Sci. 43, 2750-2756.
41. Dial, E.J. and Lichtenberger, L.M. (2002), Effect of lactoferrin on Helicobacter felis induced gastritis. Kochern. Cell Biol. 80, 113-117.
42. Dial, E.J., Dohrman, A.J., Romero, J.J. and Lichtenberger, L.M. (2005) Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents. J. Pharm. Pharmacol. 57, 93-99.
43. Diarra, M.S., Petitclerc, D. and Laçasse, P. (2002), Effect of lactoferrin in combination with penicillin on the morphology and the physiology of Staphylococcus aureus isolated from bovine mastitis. J. Dairy Sci. 85, 1141-1149.
44. Diarra, M.S., Petitclerc, D., Deschênes, E., Lessard, N., Grondin, G., Talbot, B.G. and Lacasse, P. (2003a), Lactoferrin against Staphylococcus aureus mastitis. Vet. Immunol. Immunopathol. 95, 33-42.
45. Diarra, M.S., Lacasse, P., Deschênes, E., Grondin, G., Paradis-Bleau, C. and Petitclerc, D. (2003b), Ultrastructural and cytochemical study of cell wall modification by lactoferrin, lactoferricin and penicillin G against Staphylococcus aureus. J. Electron. Microscopy 52, 207-215.
46. Di Biase, A.M., Pietrantoni, A., Tinari, A., Siciliano, R., Valenti, P., Antonini, G., Seganti, L. and Superti, F. (2003), Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J. Med. Virology 69, 495-502.
47. Dijkshoorn, L., Brouwer, C.P., Bogaards, S.J., Nemec, A., van den Broek, P.J. and Nibbering, P.H. (2004), The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48, 4919-4921.
48. Di Mario, F., Aragona, G., Dal Bo, N., Cavallaro, L., Marcon, V., Olivieri, P., Benedetti, E., Orzes, N., Marin, R., Tafner, G., Chilovi, F., De Bastiani, R., Fedrizzi, F., Franceschi, M., Salvat, M.H., Monica, F., Piazzi, L., Valiante, F., Vecchiati, U., Cavestro, G.M., Comparato, G., lori, V., Maino, M., Leandro, G., Pilotto, A., Rugge, M. and Franze, A. (2006), Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment. Pharmacol. Ther. 23, 1235-1240.
49. Drobni, P., Naslund, J. and Evander, M. (2004), Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res. 64, 63-68.
50. Dziadek, B., Dzitko, K. and Dlugonska, H. (2005), Toxoplasma gondii binds human lactoferrin but not transferrin. Exp. Parasitol. 110, 165-167.
51. Elass-Rochard, E., Roscanu, A., Legrand, D., Trif, M., Salmon, V., Motas, C., Montreuil, J. and Spik, G. (1995), Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to E. coli 055B5 lipopolysaccharide. Biochem. J. 312, 839-845.
52. Ellison III, R.T., Giehl, T.J. and Laforce, F.M. (1988), Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect. Immun. 56, 2774-2781.
53. Ellison III, R.T. and Giehl, T.J. (1991), Killing of Gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 88, 1080-1091.
54. Erdei, J., Forsgren, A. and Naidu, A.S. (1994), Lactoferrin binds to porins OmpF and OmpC in Escherichia coli. Infect. Immun. 62, 1236-1240.
55. Esteban, M.A., Rodriguez, A., Cuesta, A. and Meseguer, J. (2005), Effects of lactoferrin on non-specific immune responses of gilthead seabream (Sparus auratus L.). Fish Shellfish Immunol. 18, 109-124.
56. Faber, C., Stallmann, H.P., Lyaruu, D.M., Joosten, U., von Eiff, C., van Nieuw Amerongen, A. and Wuisman, P.I. (2005), Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob. Agents Chemother. 49, 2438-2444.
57. Fujihara, T. and Hayashi, K. (1995), Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea. Arch. Virology. 140, 1469-1472.
58. Fujita, K., Matsuda, E., Sekine, K., Iigo, M. and Tsuda, H. (2004), Lactoferrin modifies apoptosis-related gene expression in the colon of the azoxymethane-treated rat. Cancer Lett. 213, 21-29.
59. Green, G.A. (2002) Understanding NSAIDS: from aspirin to COX-2. Clin. Cornerstone 3, 50-59.
60. Grey, A., Banovic, T., Zhu, Q., Watson, M., Callon, K., Palmano, K., Ross, J., Naot, D., Reid, I.R. and Cornish, J. (2004), The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol. Endocrinol. 18, 2268-2278.
61. Grey, A., Zhu, Q., Watson, M., Callon, K. and Cornish, J. (2006), Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway. Mol. Cell Endocrinol. 251, 96-102.
62. Groenink, J., Walgreen-Weterings, E., Van't Hof, W., Veerman, E.C.I., and Nieuw Amerongen, A.V. (1999), Cationic amphipathic peptides, derived from bovine and human lactoferrins, with antimicrobial activity against oral pathogens. FEMS Microbiol. Lett. 179, 217-222.
63. Guttner, Y., Windsor, H.M., Viiala, C.H. and Marshall, B.J. (2003), Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Alimentary Pharmacol. Ther. 17, 125-129.
64. Harmsen, M.C., Swart, P.J., De Béthune, M.P., Pawel, R. and De Clercq, E. (1995) Antiviral effects of plasma and milk proteins: lactoferrin shows a potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis. 172, 380-388.
65. Hasegawa, K., Motsuxhi, W., Tanaka, S. and Dosako, S. (1994), Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J. Med. Sci. Biol 47, 73-85.
66. Hasegawa, A., Otsuki, K., Sasaki, Y., Sawada, M., Mitsukawa, K., Chiba, H., Nagatsuka, M., Okai, T. and Kato, A. (2005), Preventive effect of recombinant human lactoferrin in a rabbit preterm delivery model. Am. J. Obstet. Gynecol. 192, 1038-1043.
67. He, J. and Furmanski, P. (1995), Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373, 721-724.
68. He, K., Ludtke, S.J., Huan, H.W. and Worcester, D.L. (1995), Antimicrobial peptide pores in membranes detected by neutron in-plane scattering. Biochem. 34, 15614-15618.
69. Hendrixson, D.R., Qiu, J., Shewry, S.C., Fink, D.L., Petty, S., Baker, E.N., Flaut, A.G., and St. Geme, J.W. (2003), Human milk lactoferrin is a serine protease that cleaves haemophilus surface proteins at arginine-rich sites. Molec. Microbiol. 47, 607-617.
70. Hoek, K.S., Milne, J.M., Grieve, P.A., Dionysius, D.A. and Smith, R. (1997), Antibacterial activity of bovine lactoferrin-derived peptides. Antimicrob. Agents Chemother. 41, 54-59.
71. Hurley, W.L. and Grieve, R.C.J. (1993), Electrophoretic comparison of lactoferrin from bovine mammary secretions, milk neutrophils, and human milk. J. Dairy Sci. 76, 377-387.
72. Hutchens, T.W., Rumball, S.V. and Lönnerdal, B. (1994), Lactoferrin: structure and function. Adv. Exp. Med. Biol. 357, 21-32.
73. Hwang, P.M., Zhou, N., Shan, X., Arrowsmith, C.H. and Vogel, H.J. (1998), Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochem. 37, 4288-4298.
74. Hwang, S.A., Kruzel, M.L. and Actor, J.K. (2005), Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int. Immunopharmacol. 5, 591-599.
75. Ikadai, H., Tanaka, T., Shibahara, N., Tanaka, H., Matsuu, A., Kudo, N., Shimazaki, K., Igarashi, I. and Oyamada, T. (2005), Inhibitory effect of lactoferrin on in vitro growth of Babesia caballi. Am. J. Trop. Med. Hyg. 73, 710-712.
76. Ikeda, M., Sugiyama, K., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K. and Kato, N. (1998), Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem. Bioph. Res. Commun. 245, 549-553.
77. Ikeda, M., Nozaki, A., Sugiyama, K., Tanaka, T., Naganuma, A., Tanaka, K., Sekihara, H., Shimotohno, K., Saito, M. and Kato, N. (2000), Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Research 66, 51-63.
78. Ishikado, A., Imanaka, H., Takeuchi, T., Harada, E. and Makino, T. (2005), Liposomalization of lactoferrin enhanced its anti-inflammatory effects via oral administration. Biol. Pharm. Bull. 28, 1717-1721.
79. Iyer, S. and Lönnerdal, B. (1993), Lactoferrin, lactoferrin receptors and iron metabolism. Eur. J. Clin. Nutr. 47, 232-41.
80. Jabeen, T., Sharma, S., Singh, N., Bhushan, A. and Singh, T.P. (2005), Structure of the zinc-saturated C-terminal lobe of bovine lactoferrin at 2.0 A resolution. Acta. Crystallogr. D. Biol. Crystallogr. 61, 1107-1115.
81. Japelj, B., Pristovsek, P., Majerle, A. and Jerala, R. (2005), Structural origin of endotoxin neutralization and antimicrobial activity of a lactoferrin-based peptide. J. Biol. Chem. 280, 16955-16961.
82. Johansson, B.G. (1960), Isolation of an iron-containing red protein from human milk. Act. Chem. Scand. 14, 510-512.
83. Kang, J.H., Lee, M.K., Kim, K.L. and Hahm, K.S. (1996), Structure biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int. J. Pept. Prot. Res. 48, 357-363.
84. Kanyshkova, T.G., Buneva, V.N. and Nevinsky, G.A. (2001), Lactoferrin and its biological functions. Biochem. (Moscow) 66, 1-7.
85. Kawakami, A., Hirayama, K., Kawakami, F., Kawakami, H., Fujihara, M. and Ohtsuki, K. (2006), Purification and biochemical characterization of a fibroblast growth factor-binding protein (FGF-BP) from the lactoferrin fraction of bovine milk. Biochim. Biophys. Acta. 1760, 421-431.
86. Kim, C.W., Son, K.M., Choi, S.Y. and Kim, J. (2006), Human lactoferrin upregulates expression of KDR/Flk-1 and stimulates VEGF-A-mediated endothelial cell proliferation and migration. FEES Lett. 580, 4332-4336.
87. Kimura, M., Nam, M.S., Ohkouchi, Y., Kumura, H., Shimazaki, K.I. and Yu, D.Y. (2000), Antimicrobial peptide of Korean native goat lactoferrin and identification of the part essential for this activity. Biochem. Bioph. Res. Commun. 268, 333-336.
88. Kobayashi, S., Sato, R., Inanami, O., Yamamori, T., Yamato, O., Maede, Y., Sato, J., Kuwabara, M. and Naito, Y. (2005), Reduction of concanavalin A-induced expression of interferon-gamma by bovine lactoferrin in feline peripheral blood mononuclear cells. Vet. Immunol. Immunopathol. 105, 75-84.
89. Komine, Y., Komine, K., Kai, K., Itagaki, M., Kuroishi, T., Aso, H., Obara, Y. and Kumagai, K. (2006), Effect of combination therapy with lactoferrin and antibiotics against staphylococcal mastitis on drying cows. J. Vet. Med. Sci. 68, 205-211.
90. Konishi, M., Iwasa, M., Yamauchi, K., Sugimoto, R., Fujita, N., Kobayashi, Y., Watanabe, S., Teraguchi, S., Adachi, Y. and Kaito, M. (2006), Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol. Res. 36, 27-32.
91. Koshio, S., Yokoyama, S., Takakura, M. and Ishikawa, M. (2005), Review of lactoferrin studies in aquatic organisums. In The proceeding of 7th International Conference on Lactoferrin: Structure, Function and Applications, October 16-19, Hawaii, USA.
92. Kruzel, M.L., Harari, Y., Mailman, D. and Actor, J.K. (2002), Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in Mice. Clin. Exp. Immunol. 130, 25-31.
93. Kruzel, M.L., Bacsi, A., Choudhury, B., Sur, S. and Boldogh, I. (2006), Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma. Immunology 119, 159-166.
94. Kuhara, T., Iigo, M., Itoh, T., Ushida, Y., Sekine, K., Terada, N., Okamura, H. and Tsuda, H. (2000), Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr. Cancer. 38, 192-199.
95. Kuhara, T., Yamauchi, K., Tamura, Y. and Okamura, H. (2006), Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J. Interferon. Cytokine. Res. 26, 489-499.
96. Kuipers, M.E., de Vries-Hospers, H.G., Eikelboom, M.C., Meijer, D.K.F. and Swart, P.J. (1999), Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob. Agents Chemother. 43, 2635-2641.
97. Kumar, D.A., Raju, K.V., Settu, K., Kumanan, K. and Puvanakrishnan, R. (2006), Effect of a derivatized tetrapeptide from lactoferrin on nitric oxide mediated matrix metalloproteinase-2 production by synovial fibroblasts in collagen-induced arthritis in rats. Peptides 27, 1434-1442.
98. Kuwata, H., Yip, T.T., Tomita, M. and Hutchens, T.W. (1998), Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim. Biophys. Acta. 1429, 129-141.
99. Lanas, A. and Ferrandez, A. (2006), NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin. J. Dig. Dis. 7, 127-133.
100. Larkins, N. (2005), Potential implications of lactoferrin as a therapeutic agent. Am. J. Vet. Res. 66, 739-742.
101. Lee, N.Y., Kawai, K., Nakamura, I., Tanaka, T., Kumura, H. and Shimazaki, K. (2004), Susceptibilities against bovine lactoferrin with microorganisms isolated from mastitic milk. J. Vet. Med. Sci. 66, 1267-1269.
102. Lee, H.Y., Park, J.H., Seok, S.H., Baek, M.W., Kim, D.J., Lee, B.H., Kang, P.D., Kim, Y.S. and Park, J.H. (2005), Potential antimicrobial effects of human lactoferrin against oral infection with Listeria monocytogenes in mice. J. Med. Microbiol. 54, 1049-1054.
103. Lee, N.Y., Cheng, J.T., Enomoto, T. and Nakamura, I. (2006), The antihypertensive activity of angiotensin-converting enzyme inhibitory peptide containing in bovine lactoferrin. Chin. J. Physiol. 49, 67-73.
104. Legrand, D., Salmon, V., Coddeville, B., Benaissa, M., Plancke, Y. and Spik, G. (1995), Structural determination of two N-Linked glycans isolated from recombinant human lactoferrin expressed in BHK cells. FEBS Lett. 365, 57-60.
105. Legrand, D., Elass, E., Carpentier, M. and Mazurier, J. (2005), Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol. Life Sci. 62, 2549-2559.
106. Leitch, E.C. and Willcox, M.D. (1999), Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. J. Med. Microbiol. 48, 867-871.
107. Leon-Sicairos, N., Lopez-Soto, F., Reyes-Lopez, M., Godinez-Vargas, D., Ordaz-Pichardo, C. and de la Garza, M. (2006), Amoebicidal Activity of Milk, Apolactoferrin, sIgA and Lysozyme. Clin. Med. Res. 4, 106-113.
108. Levay, P.F. and Viljoen, M. (1995), Lactoferrin: a general review. Haematologica 80, 252-267.
109. Liceaga-Gesualdo, A., Li-Chan, E.C.Y. and Skura, B.J. (2001), Antimicrobial effect of lactoferrin digest on spores of a Penicillium spp. isolated from bottled water. Food Res. Int. 34, 501-506.
110. Longhi, C., Conte, M.P., Ranaldi, S., Penta, M., Valenti, P., Tinari, A., Superti, F. and Seganti, L. (2005), Apoptotic death of Listeria monocytogenes-infected human macrophages induced by lactoferricin B, a bovine lactoferrin-derived peptide. Int. J. Immunopathol. Pharmacol. 18, 317-325.
111. Longhi, G., Pietropaolo, V., Mischitelli, M., Longhi, C., Conte, M.P., Marchetti, M., Tinari, A., Valenti, P., Degener, A.M., Seganti, L. and Superti, F. (2006), Lactoferrin inhibits early steps of human BK. polyomavirus infection. Antiviral Res. 72, 145-152.
112. Lönnerdal, B. (2003), Lactoferrin. In Advanced Dairy Chemistry, Vol. 1: Proteins. (Eds. P. F. Fox and P.L. H. McSweeney) Kluwer Academic/Plenum Publishers, Norwell, MA, pp 449-466.
113. Lönnerdal, B. and Iyer, S. (1995), Lactoferrin: molecular structure and biological function. Annual Rev. Nutr. 15, 93-110.
114. Lu, L., Hangoc, G., Oliff, A., Chen, L., Shen, R.N. and Broxmeyer, H.E. (1987), Protective influence of lactoferrin on mice infected with the polythemia-inducing strain of Friend virus complex. Cancer Res. 47, 4184-4188.
115. Lupetti, A., Brouwer, C.P., Dogterom-Ballering, H.E., Senesi, S., Campa, M., Van Dissel, J. T. and Nibbering, P.H. (2004), Release of calcium from intracellular stores and subsequent uptake by mitochondria are essential for the candidacidal activity of an N-terminal peptide of human lactoferrin. J. Antimicrob. Chemother. 54, 603-608.
116. Machnicki, M., Zimecki, M. and Zagulski, T. (1993), Lactoferrin regulates the release of tumor necrosis factor alpha and interleukin-6 in vivo. Int. J. Exp. Path. 74, 433-439.
117. Mann, D.M., Romm, E. and Migliorini, V. (1994), Delineation of the glycosaminoglycan binding site in the human inflammatory response protein lactoferrin. J. Biol. Chem. 269, 23661-23667.
118. Marchetti, M., Longhi, C., Conte, M.P., Pisani, S., Valenti, P. and Seganti, L. (1996), Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res. 29, 221-231.
119. Marchetti, M., Pisani, S., Antonini, G., Valenti, P., Seganti, L. and Orsi, N. (1998), Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2. BioMetals 11, 89-94.
120. Matsuda, Y., Saoo, K., Hosokawa, K., Yamakawa, K., Yokohira, M., Zeng, Y., Takeuchi, H. and Imaida, K. (2006), Post-initiation chemopreventive effects of dietary bovine lactoferrin on 4-(methylnitrosamino)-1 -(3-pyridyl)-1 -butanoneinduced lung tumorigenesis in female A/J mice. Cancer Lett. 246, 41-46.
121. Matthews, T.H.J., Nair, C.D.G., Lawrence, M.K. and Tyrrel, D.A.J. (1976), Antiviral activity in milk of possible clinical importance. Lancet 1, 1387-1389.
122. McCann, K.B., Lee, A., Wan, J., Roginski, H. and Coventry, M.J. (2003), The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. J. Appl. Microbiol. 95, 1026-1033.
123. s2- casein. Int. Dairy J. 15, 133-143.
124. McKeown, S.T., Lundy, F.T., Nelson, J., Lockhart, D., Irwin, C.R., Cowan, C.G. and Marley, J.J. (2006), The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol. 42, 685-690.
125. Medina, I., Tombo, L., Satue-Gracia, M.T., German, J.B. and Frankel, E.N. (2002), Effects of natural phenolic compounds on the antioxidant activity of lactoferrin in liposomes and oil-in-water emulsions. J. Agric. Food Chem. 50, 2392-2399.
126. Miehlke, S., Reddy, R., Osato, M., Ward, P., Conneely, O. and Graham, D. (1996), Direct activity of recombinant human lactoferrin against Helicobacter pylori. J. Clin. Microbiol. 34, 2593-2594.
127. Murdock, C.A. and Matthews, K.R. (2002), Antibacterial activity of pepsin-digested lactoferrin on foodborne pathogens in buffered broth systems and ultra-high temperature milk with EDTA. J. Appl. Microbiol. 93, 850-856.
128. Na, Y.J., Han, S.B., Kang, J.S., Yoon, Y.D., Park, S.K., Kim, H.M., Yang, K.H. and Joe, C.O. (2004), Lactoferrin works as a new LPS-binding protein in inflammatory activation of macrophages. Int. Immunopharmacol. 4, 1187-1199.
129. Naidu, A.S. (2001), Immobilized lactoferrin antimicrobial agents and the use thereof. Patent No. US 6,172,040 B1, 9JAN2001.
130. Naidu, A.S. (2002), Activated lactoferrin-A new approach to meat safety. Food Technol. 56 (3), 40-45.
131. Naidu, A.S. and Arnold, R.R. (1997), Influence of lactoferrin on host-microbe interactions. In Lactoferrin: Interactions and Biological Functions (Eds T.W. Hutchens and B. Lönnerdal). Humana Press Inc., Totowa, NJ, pp 259-275.
132. Naidu, A.S., Fowler, R.S., Martinez, C., Chen, J. and Tulpinski, J. (2004), Activated lactoferrin and fluconazole synergism against Candida albicans and Candida glabrata vaginal isolates. J. Reprod. Med. 49, 800-807.
133. Naot, D., Grey, A., Reid, I.R. and Cornish, J. (2005), Lactoferrin - a novel bone growth factor. Clin. Med. Res. 3, 93-101.
134. Nibbering, P.H., Ravensbergen, E., Welling, M.M., van Berkel, L.A., van Berkel, P.H.C., Pauwels, E.K.J. and Nuijens, J.H. (2001), Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibioticresistant bacteria. Infect. Immun. 69, 1469-1476.
135. Nielsen, N.S., Petersen, A., Meyer, A.S., Timm-Heinrich, M. and Jacobsen, C. (2004), Effects of lactoferrin, phytic acid, and EDTA on oxidation in two food emulsions enriched with long-chain polyunsaturated fatty acids. J. Agric. Food Chem. 52, 7690-7699.
136. Nikawa, H., Samaranayake, L.P., Tenovuo, J. and Hamada, T. (1994), The effect of antifungal agents on the in vitro susceptibility of Candida albicans to apo-lactoferrin. Arch. Oral Biol. 39, 921-923.
137. Nozaki, A., Tanaka, K., Naganuma, A. and Kato, N. (2002), Recent advances of basic research and clinical application of lactoferrin as an antiviral reagent against chronic hepatitis C. Jpn J. Clin. Med. 60, 819-29.
138. Odell, E.W., Sarra, R., Foxworthy, M., Chapple, D.S. and Evans, R.W. (1996), Antibacterial activity of peptides homologous to a loop region in human lactoferrin. FEBS Lett. 382, 175-178.
139. Oguchi, S., Walker, W.A. and Sanderson, I.R. (1995), Iron saturation alters the effect of lactoferrin on the proliferation and differentiation of human enterocytes (Caco-2 cells). Biol. Neonate. 67, 330-339.
140. Okamoto, T., Tanida, T., Wei, B., Ueta, E., Yamamoto, T. and Osaki, T. (2004), Regulation of fungal infection by a combination of amphotericin B and peptide 2, a lactoferrin peptide that activates neutrophils. Clin. Diagn. Lab. Immunol. 11, 1111-1119.
141. Okuda, M., Nakazawa, T., Yamauchi, K., Miyashiro, E., Koizumi, R., Booka, M., Teraguchi, S., Tamura, Y., Yoshikawa, N., Adachi, Y. and Imoto, I. (2005), Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study. J. Infect. Chemother. 11, 265-269.
142. Otsuki, K., Yakuwa, K., Sawada, M., Hasegawa, A., Sasaki, Y., Mitsukawa, K., Chiba, H., Nagatsuka, M., Saito, H. and Okai, T. (2005), Recombinant human lactoferrin has preventive effects on lipopolysaccharide-induced preterm delivery and production of inflammatory cytokines in mice. J. Perinat. Med. 33, 320-323.
143. Pan, Y., Lee, A., Wan, J., Coventry, M.J., Michalski, W.P., Shiell, B. and Roginski, H. (2006), Antiviral properties of milk proteins and their derivatives. Int. Dairy J. 16, 1252-1261.
144. Papo, N. and Shai, Y. (2003), Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? Peptide 24, 1693-1703.
145. Pietrantoni, A., Ammendolia, M.G., Tinari, A., Siciliano, R., Valenti, P. and Superti, F. (2006), Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res. 69, 98-106.
146. Pihlanto, A. and Korhonen, H. (2003), Bioactive peptides and proteins. Adv. Food Nutr. Res. 47, 175-276.
147. Powers, J.S. and Hancock, R.E.W. (2003), The relationship between peptide structure and antibacterial activity. Peptide 24, 1681-1691.
148. Puddu, P., Borghi, P., Gessani, S., Valenti, P., Belardelli, F. and Seganti, L. (1998), Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int. J. Biochem. Cell Biol. 30, 1055-1062.
149. Recio, I. and Visser, S. (2000), Antibacterial and binding characteristics of bovine, ovine and caprine lactoferrins: a comparative study. Int. Dairy J. 10, 597-605.
150. Rainard, P. (1986), Bacteriostatic activity of bovine milk lactoferrin against mastitic bacteria. Vet. Microbiol. 11, 387-392.
151. Roderiquez, G., Oravecz, T., Yanagishita, M., Bou-habib, D.C., Mostowski, H. and Norcross, M.A. (1995), Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp 120-gp41. J. Virology 69, 2233-2239.
152. Rogan, M.P., Taggart, C.C., Greene, C.M., Murphy, P.G., O'Neill, S.I. and McElvaney, N.G. (2004), Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J. Infect. Dis. 190, 1245-1253.
153. 2+ binding to bovine lactoferrin enhances protein stability and influences the release of bacterial lipopolysaccharide. Biochem. Cell Biol. 80, 41-48.
154. Rostand, K.S. and Esko, J.D. (1997), Microbial adherence to and invasion through proteoglycans. Infect. Immun. 65, 1-8.
155. Sakai, T., Banno, Y., Kato, Y., Nozawa, Y. and Kawaguchi, M. (2006) Pepsin-digested bovine lactoferrin induces apoptotic cell death with JNK/SAPK activation in oral cancer cells. J. Pharmacol. Sci. 98, 41-48.
156. Sallman, F.R., Baveye-Descamps, S., Pattus, F., Salmon, V., Branza, N., Spik, G. and Legrand, D. (2000), Binding of human lactoferrin to Escherichia coli porins: a biochemical study. Excerpta Medico. Int. Congress Series 1195, 77-84.
157. Santagati, M.G., La Terra Mule, S., Amico, C., Pistone, M., Rusciano, D. and Enea, V. (2005), Lactoferrin expression by bovine ocular surface epithelia: a primary cell culture model to study lactoferrin gene promoter activity. Ophthalmic. Res. 37, 270-8.
158. Sasaki, Y., Otsuki, K., Hasegawa, A., Sawada, M., Chiba, H., Negishi, M., Nagatsuka, M. and Okai, T. (2004), Preventive effect of recombinant human lactoferrin on lipopolysaccharide-induced preterm delivery in mice. Acta. Obstet. Gynecol. Scand. 83, 1035-1038.
159. Seganti, L., Di Biase, A.M., Marchetti, M., Pietrantoni, A., Tinari, A. and Superti, F. (2004), Antiviral activity of lactoferrin towards naked viruses. Biomelals 17, 295-299.
160. Sekine, K., Watanabe, E., Nakamura, J. Takasuka, N., Kim, D.J., Asamoto, M., Krutovskikh, V., Baba-Toriyama, H., Ota, T., Moore, M.A., Masuda, M., Sugimoto, H., Nishino, H., Kakizoe, T. and Tsuda, H. (1997), Inhibition of azoxymethaneinitiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J. Cancer Res. 88, 523-526.
161. Sherman M.P. and Petrak K. (2005), Lactoferrin-enhanced anoikis: a defense against neonatal necrotizing enterocolitis. Med. Hypotheses 65, 478-482.
162. Shimamura, M., Yamamoto, Y., Ashino, H., Oikawa, T., Hazato, T., Tsuda, H. and ligo, M. (2004), Bovine lactoferrin inhibits tumor-induced angiogenesis. Int. J. Cancer 111, 111-116.
163. Shimazaki, K. (2000), Lactoferrin: A marvelous protein in milk? Animal Sci. J. 71, 329-347.
164. Shimizu, K., Matsuzawa, H., Okada, K., Tazume, S., Dosako, S., Kawasaki, Y., Hashimoto, K. and Koga, Y. (1996), Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell-dependent augmentation of natural killer cell activity. Arch. Virology 141, 1875-1889.
165. Shin, K., Wakabayashi, H., Yamauchi, K., Teraguchi, S., Tamura. Y., Kurokawa, M. and Shiraki, K. (2005), Effects of orally administered bovine lactoferrin and lactoperoxidase on influenza virus infection in mice. J. Med. Microbiol. 54, 717-723.
166. Shiota, M., Uchida, T., Oda, T. and Kawakami H. (2006), Utilization of lactoferrin as an iron-stabilizer for soybean and fish oil. J. Food Sci. 71, 120-123.
167. Sørensen, M. and Sørensen, S.P.L. (1939), The protein in whey. C. R. Trav. Lab. Carlsberg 23, 55-99.
168. Spik, G., Cheron, A., Montreuil, J. and Dolby, J.M. (1978), Bacteriostasis of a milksensitive strain of Escherichia coli by immunoglobulins and iron-binding proteins in association. Immunol. 35, 663-671.
169. Stallmann, H.P., Faber, C., Bronckers, A.L., de Blieck-Hogervorst, J.M., Brouwer, C.P., Amerongen, A.V. and Wuisman, P.I. (2005), Histatin and lactoferrin derived peptides: antimicrobial properties and effects on mammalian cells. Peptides 26, 2355-2359.
170. Steijns, J.M., and Van Hooijdonk, A.C.M. (2000), Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br. J. Nutr. 84, 11-17.
171. Stephens, S., Dolby, J.M., Montreuil, J. and Spik, G. (1980), Differences in inhibition of the growth of commensal and enteropathogenic strains of Escherichia coli by lactotransferrin and secretory immunoglobulin A isolated from human milk. Immunol. 41, 597-603.
172. Sundara B.N., Acharya K.R., Singh T.P. and Krishnaswamy S. (2005), High-resoluton diffraction from crystals of a membrane-protein complex: bacterial outer membrane protein OmpC complexed with the antibacterial eukaryotic protein lactoferrin. Acta Crystallograph Sect. F. Struct. Biol. Cryst. Commun. 61, 773-775.
173. Superti, F., Ammendolia, M.G., Valenti, P. and Seganti, L. (1997), Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocytelike cell line HT-29. Med. Microbiol. Immunol 186, 83-91.
174. Superti, F., Pietrantoni, A., Di Biase, A.M., Longhi, C., Valenti, P. and Tinari, A. (2005), Inv-mediated apoptosis of epithelial cells infected with enteropathogenic Yersinia: a protective effect of lactoferrin Res. Microbiol. 156, 728-37.
175. Suzuki, Y.A., Lopez, V. and Lönnerdal, B. (2005), Mammalian lactoferrin receptors: structure and function. Cell Mol. Life Sci. 62, 2560-2575.
176. Swiss-Prot (2007) Swiss-Prot database http://www.expasy.org/sprot/.
177. Swart, P.J., Kuipers, M.E., Smit, C., Pauwels, R., De Béthune, M.P., De Clercoq, E., Meijer, D.K.F. and Huisman, J.G. (1996), Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res. Human Retroviruses 12, 769-775.
178. Swart, P.J., Harmsen, M.C., Kuipers, M.E., Van Dijk, A.A., Van der Strate, B.W.A., Van Berkel, P.H.C., Huijens, J.H., Smit, C., Witvrouw, M., De Clercq, E., De Béthune, M., Pauwels, R. and Meijer, D.K.F. (1999), Charge modification of plasma and milk proteins results in antiviral active compounds. J. Pept. Sci. 5, 563-576.
179. Tamaki, Y., Shimizu, Y. and Ando, K. (2005), Lactoferrin in dentistry. In The proceeding of 7th International Conference on Lactoferrin: Structure, Function and Applications, October 16-19, Hawaii, US.
180. Tanaka, T., Omata, Y., Saito, A., Shimazaki, K., Yamauchi, K., Takase, M., Kawase, K., Igarashi, I. and Suzuki, N. (1995), Toxoplasma gondil: parasiticidal effects of bovine lactoferricin against parasites. Exp. Parasitai. 81, 614-617.
181. Tanida, T., Okamoto, T., Ueta, E., Yamamoto, T. and Osaki, T. (2006), Antimicrobial peptides enhance the candidacidal activity of antifungal drugs by promoting the efflux of ATP from Candida cells. J. Antimicrob. Chemother. 57, 94-103.
182. Tenovuo, J. (2002), Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in Xerostomia: efficacy and safety. Oral Dis. 8, 23-29.
183. Teraguchi, S., Shin, K., Fukuwatari, Y. and Shimamura, S. (1996), Glycans of bovine lactoferin function as receptors for the type 1 fimbrial lectin of Escherichia coli. Infect. Immun. 64, 1075-1077.
184. Tinari, A., Pietrantoni, A., Ammendolia, M.G., Valenti, P. and Superti, F. (2005), Inhibitory activity of bovine lactoferrin against echovirus induced programmed cell death in vitro. Int. J. Antimicrob. Agents 25, 433-438.
185. Ueta, E., Tanida, T. and Osaki, T. (2001), A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. J. Pept. Res. 57, 240-249.
186. Valenti, P., Marchetti, M., Superti, F., Amendolia, M.G., Puddu, P., Gessani, S., Borghi, P., Belardelli, F., Antonini, G. and Seganti, L. (1998), Antiviral activity of lactoferrin. In Advances in Lactoferrin Research (Eds G. Spik, D. Legrand, J. Mazurier, A. Pierce and J.P. Perraudin). Plenum Press, New York, pp 199-203.
187. Valenti, P., Torcia, F., Berlutti, F., Pacifici, E., Ebano, V., Moscarini, M. and Paesano, R. (2005), Oral administration of lactoferrin increases hemoglobin and sideremia in pregnant woman. In The proceeding of 7th International Conference on Lactoferrin: Structure, Function and Applications, October 16-9, Hawaii, US.
188. Van Berkel, P.H.C., Geerts, M.E.J., Veen, H.V., Kooiman, P.M. and Piepper, F.R. (1995), Glycosylated and unglycosylated human lactoferrins both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their susceptibilities towards tryptic proteolysis. Biochem. J. 312, 107-114.
189. 138 in human lactoferrin: a study with glycosylation-site mutants. Biochem. J. 319, 117-122.
190. van Berkel, P.H.C., Geerts, M.E.J., Van Veen, H.A., Mericskay, M., De Boer, H.A. and Nuijens, J.H. (1997), N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem. J. 328, 145-151.
191. van der Kraan, M.I.A., Groenink, J., Nazmi, K., Veerman, E.C.I., Bolscher, J.G.M. and Nieuw Amerongen, A.V. (2004), Lactoferrampin: a novel antimicrobial peptide in the Nl-domain of bovine lactoferrin. Peptide 25, 177-183.
192. van der Kraan, M.I., Nazmi, K., Teeken, A., Groenink, J., van 't Hof, W., Veerman, E.C., Bolscher, J.G. and Nieuw Amerongen, A.V. (2005a), Lactoferrampin, an antimicrobial peptide of bovine lactoferrin, exerts its candidacidal activity by a cluster of positively charged residues at the C-terminus in combination with a helixfacilitating N-terminal part. Biol. Chem. 386, 137-42.
193. van der Kraan, M.I., van Marie, J., Nazmi, K., Groenink, J., van 't Hof, W., Veerman, E. C., Bolscher, J.G. and Nieuw Amerongen, A.V. (2005b), Ultrastructural effects of antimicrobial peptides from bovine lactoferrin on the membranes of Candida albicans and Escherichia coli. Peptides 26, 1537-1542.
194. van der Strate, B.W.A., Beljaars, L., Molema, G., Harmsen, M.C., Meijer, D.K.F. (2001), Antiviral activities of lactoferrin. Antiviral Res. 52, 225-239.
195. van Hooijdonk, A.C.M., Kussendrager, K.D. and Steijns, J.M. (2000), In vivo antimicrobial and antiviral activity of components in bovine milk and colostrum involved in non-specific defence. Br. J. Nutr. 84, S127-S134.
196. Varadhachary, A., Wolf, J.S., Petrak, K., O'Malley, B.W. Jr, Spadaro, M., Curcio, C., Forni, G. and Pericle, F. (2004), Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Im. J. Cancer 111, 398-403.
197. Viejo-Diaz, M., Andres, M.T. and Fierro, J.F. (2004), Effects of human lactoferrin on the cytoplasmic membrane of Candida albicans cells related with its candidacidal activity. FEMS Immunol. Med. Microbiol. 42, 181-185.
198. Viejo-Diaz, M., Andres, M.T. and Fierro, J.F. (2005), Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1. Antimicrob. Agents Chemother. 49, 2583-2588.
199. Waarts, B., Aneke, O.J.C., Smit, J.M., Kimata, K., Bittman, R., Meijer, D.K.F. and Wilschut, J. (2005), Antiviral activity of human lactoferrin: Inhibition of alphavirus interaction with heparan sulfate. Virology 333, 284-292.
200. WaKabongo, M., Stucki, Z.N., Torbert, D.P. and Olweny, J. (2005), Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas. J. Am. Osteopath. Assoc. 105, 25-26.
201. Ward, P.P., Paz, E. and Conneely, O.M. (2005), Multifunctional roles of lactoferrin: a critical overview. Cell Mol. Life Sci. 62, 2540-2548.
202. Wakabayashi, H., Takakura, N., Yamauchi, K. and Tamura, Y. (2006), Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin. Vaccine Immunol. 13, 239-245.
203. Wei, Z., Nishimura, T. and Yoshida, S. (2001), Characterization of glycans in a lactoferrin isoform, lactoferrin-a. J. Dairy Sci. 84, 2584-2590.
204. Wu, H.F., Monroe, D.M. and Church, F.C. (1995), Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch. Biochem. Biophys. 317, 85-92.
205. WuDunn, D. and Spear, P. G. (1989), Initial interaction of herpes simplex virus with cells is binding to heparan sulphate. J. Virology 63, 52-58.
206. Xiao, Y., Monitto, C.L., Minhas, K.M. and Sidransky, D. (2004), Lactoferrin downregulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin. Cancer Res. 10, 8683-8686.
207. Yajima, M., Yajima, T. and Kuwata, T. (2005), Intraperitoneal injection of lactoferrin ameliorates severe albumin extravasation and neutrophilia in LPS-induced inflammation in neonatal rats. Biomed. Res. 26, 249-255.
208. Ye, X., Nishimura, T. and Yoshida, S. (1997), Characterization of the protein and glycan moieties in different forms of bovine lactoferrin. Biosci. Biotech. Biochem. 61, 782-786.
209. Ye, X.Y., Wang, H.X., Liu, F. and Ng, T.B. (2000), Ribonuclease, cell-free translationinhibitory and Superoxide radical scavenging activities of the iron-binding protein actoferrin from bovine milk. Int. J. Biochem. Cell Biol. 32, 235-241.
210. Yi, M., Kaneko, S., Yu, D.Y. and Murakami, S. (1997), Hepatitis C virus envelope proteins bind lactoferrin. J. Virology 71, 5997-6002.
211. Yoo, Y.C., Watanabe, S., Watanabe, R., Hata, K., Shimazaki, K. and Azuma, I. (1997), Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J. Cancer Res. 88, 184-190.
212. Zhao, X.Y. and Hutchens, T.W. (1994), Proposed mechanisms for the involvement of lactoferrin in the hydrolysis of nucleic acid. In Lactoferrin: Structure and Function (Eds T.W. Hutchens, S.V. Rumball, and B. Lönnerdal). Plenum Press, New York.
213. Zheng, J., Ather, J.L., Sonstegard, T.S. and Kerr, D.E. (2005), Characterization of the infection-responsive bovine lactoferrin promoter. Gene 353, 107-117.
214. Zimecki, M., Artym, J., Chodaczek, G., Kocieba, M. and Kruzel, M.L. (2004), Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: Relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflammation Res. 53, 292-296.
215. Zimecki, M., Artym, J., Chodaczek, G., Kocieba, M. and Kruzel, M. (2005), Effects of lactoferrin on the immune response modified by the immobilization stress. Pharmacol. Rep. 57, 811-817.
216. Zuccotti, G.V., Salvini, F., Riva, E. and Agostoni, C. (2006), Oral lactoferrin in HIV1 vertically infected children: an observational follow-up of plasma viral load and immune parameters. J. Int. Med. Res. 34, 88-94.
217. Zullo, A., De Francesco, V., Scaccianoce, G., Hassan, C., Panarese, A., Piglionica, D., Panella, C., Morini, S. and lerardi, E. (2005), Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study. Dig. Liver Dis. 37, 496-500.